SIRT1 and pancreatic neoplasm: This SIRT1-selective inhibitor showed a strong antiproliferative effect in pancreatic cancer cells and enhanced sensitivity of cancer cells to gemcitabine treatment through increased apoptosis (Zhang et al., 2014; Oon et al., 2015).